Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Biogen is paying up to $1.45 billion in milestones to Neomorph for a molecular glue collaboration targeting Alzheimer's disease, rare neurological diseases,…
Neomorph has secured its second multi-billion-dollar pharma deal of 2024, signing a molecular glue collaboration with Biogen worth up to $1.45 billion across…
Neomorph closed a $100 million Series B on April 14, 2026, led by Deerfield Management with new participation from Regeneron Ventures, Longwood Fund,…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Biogen and Neomorph announced research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and immunological diseases. Neomorph receives upfront plus potential milestones totaling up to $1.45B, research cost reimbursement, and mid-single to low-double digit royalties. Biogen advances clinical candidates.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Inc. / Neomorph Inc. (this deal) | 2024 | $1.4B | — |
| Biogen Inc. / Reata Pharmaceuticals | 2023 | $7.3B | 73 |
| Biogen Inc. / Human Immunology Biosciences | 2024 | $1.1B | 68 |
| Biogen Inc. / RayThera Inc. | 2026 | $1.0B | 52 |
| Biogen Inc. / Bristol-Myers Squibb Company | 2017 | $710M | 15 |
| Biogen Inc. / Nightstar Therapeutics | 2019 | $800M | — |
| Biogen Inc. / TJ Biopharma Co., Ltd. | 2026 | $850M | — |
← Browse all deals · How we score deals
More: 2024 deals · Biogen Inc. deals · Immunology deals